We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Vaccination with CD133 melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor.
- Authors
Miyabayashi, Takao; Kagamu, Hiroshi; Koshio, Jun; Ichikawa, Kosuke; Baba, Junko; Watanabe, Satoshi; Tanaka, Hiroshi; Tanaka, Junta; Yoshizawa, Hirohisa; Nakata, Koh; Narita, Ichiei
- Abstract
Accumulating evidence suggests that cancer cells possess a small subpopulation that survives during potentially lethal stresses, including chemotherapy, radiation treatment, and molecular-targeting therapy. CD133 is a putative marker that distinguishes a minor subpopulation from normal differentiated tumor cells in many cancers. Although it is necessary to eradicate all cancer cells to obtain a cure, effective treatment to eliminate the CD133 treatment-tolerant cells has not been elucidated. In this study, we demonstrated that a CD133 subpopulation in murine melanoma is immunogenic and that effector T cells specific for the CD133 melanoma cells mediated potent antitumor reactivity, curing the mice of the parental melanoma. CD133 melanoma antigens preferentially induced type 17 T helper (Th17) cells and Th1 cells but not Th2 cells. CD133 melanoma cell-specific CD4 T-cell treatment eradicated not only CD133 tumor cells but also CD133 tumor cells while inducing long-lasting accumulation of lymphocytes and dendritic cells with upregulated MHC class II in tumor tissues. Further, the treatment prevented regulatory T-cell induction. These results indicate that T-cell immunotherapy is a promising treatment option to eradicate CD133 drug-tolerant cells to obtain a cure for cancer.
- Subjects
VACCINATION; MELANOMA; LABORATORY mice; T cells; MURINE sarcoma viruses; DRUG therapy; IMMUNOTHERAPY
- Publication
Cancer Immunology, Immunotherapy, 2011, Vol 60, Issue 11, p1597
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-011-1063-x